NCT03810911View on ClinicalTrials.gov

Mechanisms of EPO-induced Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Chronic Kidney DiseaseBlood PressureAnemia
Interventions
DRUG

Darbepoetin

Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.

Trial Locations (1)

46202-2884

Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03810911 - Mechanisms of EPO-induced Hypertension | Biotech Hunter | Biotech Hunter